Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder
OwnerRyo Yoshimoto, Akane Ishihara +2inventors
InventorsRyo Yoshimoto, Akane Ishihara, Akio Kanatani, Shigeru Tokita
Life of this patent
Estimating the term…
Abstract
Disclosed are: novel use of an agonist histamine receptor H3 (e.g., Imetit) for prevention of obesity or the reduction of food intake; a method for evaluation of a compound for use as a therapeutic agent targeted to histamine receptor HR protein; and a compound provided by the method.
Claims17
1-12. (canceled)
A method of treating a disease selected from a lipid metabolic disease and a glucose metabolic disease in a patient in need of such treatment comprising administration of a therapeutically effective amount of a histamine H3 agonist.
A method for assaying a compound used in the treatment of a lipid metabolic disease, comprising steps of:
- introducing a histamine H3 receptor gene into a cell, so as to prepare a cell that expresses a histamine H3 receptor;
- bringing a test compound into contact with said cell;
- and
- detecting the specific binding of said test compound to said histamine H3 receptor.
A method for assaying a compound used in the treatment of a lipid metabolic disease, comprising steps of:
- introducing a histamine H3 receptor gene into a cell, so as to prepare a cell that expresses a histamine H3 receptor;
- bringing a test compound into contact with said cell;
- measuring an activity of an intracellular signaling agent generated as a result of the contact;
- and
- comparing the thus measured activity with an activity of the intracellular signaling agent in a case where a test compound is not contacted with said cell.
A method for assaying a compound used in the treatment of a lipid metabolic disease, comprising steps of:
- introducing a histamine H3 receptor gene into a cell, so as to prepare a cell that expresses a histamine H3 receptor;
- bringing a test compound into contact with said cell;
- measuring an expression level of the histamine H3 receptor or an intracellular signaling agent mediated by the histamine H3 receptor;
- and
- selecting a test compound that has increased or decreased the expression level of the histamine H3 receptor or the intracellular signaling agent mediated by the histamine H3 receptor, when compared with a case where such a test compound is not contacted with said cell.
A method for assaying a compound used in the treatment of a lipid metabolic disease, comprising steps of:
- bringing a test compound into contact with a histamine H3 receptor;
- and
- detecting a change in the activity of the histamine H3 receptor due to the contact.
Dependencies are inferred from the claim text.